Circular No. 16-BYT/TT guiding the implementation of Decision No. 104-HĐBT-1987 on retail prices of medicines issued by the Ministry of Health

Circular No. 16-BYT/TT guides the implementation of Decision No. 104-HĐBT-1987 on retail prices of medicines, stipulates standard prices for various types of medicines, and requires uniform application nationwide from July 15, 1987.

문서 번호16-BYT/TT
문서 유형Circular
발행 기관Ministry of Health
서명자Nguyễn Duy Cương — Thứ trưởng
업데이트21. 06. 2026
분야Uncategorized
발행일07. 07. 1987
발효일15. 07. 1987
효력 만료일—
상태In effect
✦ 스마트 요약

Circular No. 16-BYT/TT guides the implementation of Decision No. 104-HĐBT-1987 on retail prices of medicines, stipulates standard prices for various types of medicines, and requires uniform application nationwide from July 15, 1987.

적용 범위

Medicine production and trading units, pharmacies, hospitals, outpatient clinics, public and private healthcare facilities

핵심 사항

  • All medicine production and trading units must sell medicines at the prescribed price without exceeding the standard level (Point 1).
  • If there is a factory producing similar products but with different formulas, concentrations, or packaging methods, it must register the drug name, and the Ministry of Health will decide on the retail price (Point 2).
  • Units are not allowed to arbitrarily increase the retail price of medicines not included in the published list (Point 3).
  • Prioritize distribution to treatment units and strengthen market management to prevent abuse and theft of medicines (Point 4).
  • Healthcare facilities need to recalculate operating costs to request financial supplements from relevant authorities in line with changes in medicine prices (Point 5).

🌐 이 문서의 사회적 영향

  • To stabilize the medicine market and prevent arbitrary price increases.
  • Increased costs for healthcare units due to purchasing medicines at new prices.
  • Improve the quality and efficiency of medicine usage in the healthcare sector.
  • Financial difficulties for private healthcare facilities that do not receive state budget support.

❓ 자주 묻는 질문

Are all types of medicines subject to the new retail prices?

No, only those medicines listed in the catalog are subject to the new prices. Other types of medicines retain their original prices.

What should medicine production and trading units do if they have similar products but with different formulas?

The unit must register the drug name with the Ministry of Health to obtain a decision on the retail price for the new product.

Is there any specific regulation regarding inventory checks and price labeling?

Inventory checks and price labeling shall be carried out according to Circular No. 19-BYT/TT dated September 27, 1985.

What actions should healthcare units take to ensure operational funding?

Units must recalculate costs and request financial supplements from relevant authorities in line with changes in medicine prices.

Are there penalties for arbitrary price increases?

Strict penalties will be imposed on violations related to management, exploitation, and arbitrary price increases.

전문

MINISTRY OF HEALTH
********

SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness
********

NUMBER: 16-BYT/TT

HA NOI, July 7, 1987

 

CIRCULAR

DIRECTIVE NO. 16-BYT/TT OF THE MINISTRY OF HEALTH ON JULY 7, 1987 GUIDING THE IMPLEMENTATION OF THE RESOLUTION OF THE STATE COUNCIL NO. 104-HDBT OF JUNE 30, 1987 ON THE RETAIL PRICES OF MEDICINES

On June 30, 1987, the State Council issued Decision No. 104-HDBT stipulating standard prices for retail sales of medicines, to be uniformly applied throughout the country. Based on these standard prices under the current system of price management division and delegation, the National Price Commission issued Decision No. 375-UBVG on July 6, 1987, and the Ministry of Health issued Decision No. 553-BYT/QD on July 6, 1987, setting retail prices, uniformly applied nationwide, for certain key medicines.

To ensure uniform and timely implementation, in the spirit of fully grasping the guiding principles on retail prices set forth by the State Council, the Ministry of Health provides guidance on specific issues as follows:

1. The prices established are uniformly applicable throughout the country within the entire health care network from central to communal levels, in all pharmaceutical production and trading units (Pharmaceutical Factories, Combined Pharmaceutical Factories, Pharmaceutical Companies, drugstores...) as well as in all public health institutions (hospitals, medical schools, research institutes, specialized clinics, commune health centers, etc...). No unit, regardless of location, may sell medicines at a higher price than that prescribed.

2. In the current situation, a product may be produced by several central and local pharmaceutical factories using self-balanced raw materials. The established prices apply to all products with the same name, form, dosage, and packaging. If a factory produces a product with similar raw materials and form as those already priced by the State Council, the National Price Commission, and the Ministry of Health, but with different formulas, dosages, or packaging, the unit must register the drug name with the Ministry of Health (Department of Pharmacy and Vietnam Pharmaceutical Enterprises Association).

Retail prices for such products will be determined by the Ministry of Health if they are produced by Central Pharmaceutical Factories, or by Provincial Price Commissions if they are produced by Provincial Combined Pharmaceutical Factories (or Provincial Pharmaceutical Factories).

District and county drugstores, as well as pharmaceutical units in various sectors and hospitals, are completely prohibited from producing similar products under similar systems or selling such products on the market.

3. Apart from the prices of the types of medicines already established, other types of medicines will continue to follow the old prices. No unit, regardless of location, may arbitrarily increase prices for any reason. Production units must continue to implement their assigned production plans; if difficulties arise, they should promptly report to the Ministry of Health (Vietnam Pharmaceutical Enterprises Association) to take timely measures to address them.

4. The established prices still have significant differences compared to market prices. The supply of medicines is limited. Therefore, on one hand, priority distribution of state-managed products (those now priced or yet to be priced) to treatment units (clinics, hospitals) must be implemented, while on the other hand, efforts must be strengthened to manage, consolidate distribution networks, and apply reasonable and safe usage policies, actively combating misuse and theft, preventing medicines from being diverted, and enhancing market regulation.

At the production stage, active measures must be taken to conserve raw materials and supplies, increase labor productivity, continuously improve product quality, and reduce costs.

5. The new retail prices will significantly impact the budgets of health units, particularly hospitals. According to the State Council's decision (Decision No. 104-HDBT, Article 2), "The Finance Department will increase the budget for health facilities to align with changes in medicine prices:"

Provincial Health Departments, Health Boards, District and County Health Offices, and especially treatment units and hospital outpatient departments need to recalculate specifically to request financial authorities to supplement necessary funds for their operations, without affecting patient care.

However, broad explanations must be provided to the public, especially patients. Revising retail prices is an objective requirement aimed at creating conditions for the health sector to develop pharmaceutical production and better meet the needs of disease prevention and treatment for the people.

6. The new retail prices will be implemented from July 15, 1987. Central units and Provincial Health Departments must immediately conduct strict inventory checks. The dissemination, posting, and establishment of inspection committees will follow Point 6 and Section II of the Ministry of Health's Directive No. 19-BYT/TT dated September 27, 1985.

Provincial Health Departments must direct district and county drugstores to strictly comply with national regulations and those of the Ministry.

The general spirit is to implement everything as quickly and seriously as possible.

During implementation, enhanced monitoring, urging, inspection, and regular auditing of the enforcement of state-guided prices are required. Rewards and recommendations for rewards should be given to those who perform well and actively. At the same time, strict penalties should be imposed on violations related to management, exploitation, and arbitrary price increases.

The above are the main points that central units and localities need to thoroughly understand and plan to implement effectively.

During implementation, if there are any difficulties, they should be reported promptly so that the Ministry can take appropriate and timely measures.

 

Nguyen Duy Cuong

(Signed)

 

이 문서의 원본 파일을 업데이트하는 중입니다. 전문을 먼저 확인하시고 나중에 다시 확인해 주세요.

관계도

↑ 근거 및 이 문서에 영향을 주는 문서
근거 1
16-BYT/TT
Circular No. 16-BYT/TT guiding the implementation of Decision No. 104-HĐBT-1987 on retail prices of medicines issued by the Ministry of Health
In effect
↓ 이 문서의 영향을 받는 문서

문서를 클릭하면 열립니다. 빨간 테두리=효력을 변경하는 관계.